Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 13/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 9/20 | 0.49 |
| ▸ | SCN5A | Q14524 | 9/20 | 0.49 |
| ▸ | AURKA | O14965 | 2/20 | 0.43 |
| ▸ | SYK | P43405 | 1/20 | 0.42 |
| ▸ | IKBKB | O14920 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.41 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3226666 | 0.87 | SCN9A (0.54) | SCN9AKCNH2SCN5AAURKAIKBKB | |
| SCHEMBL12354928 | 0.83 | IGF1R (0.49) | SCN9AKCNH2SCN5A | |
| SCHEMBL1935543 | 0.80 | ROCK1 (0.58) | SCN9AKCNH2AURKA | |
| SCHEMBL12346572 | 0.79 | SCN9A (0.60) | SCN9AKCNH2SCN5ASYK | |
| SCHEMBL1936787 | 0.76 | SCN9A (0.45) | SCN9AKCNH2SCN5AAURKASYK | |
| SCHEMBL12346576 | 0.76 | SCN9A (0.64) | SCN9AKCNH2SCN5AAURKASYK | |
| SCHEMBL1934601 | 0.75 | SCN9A (0.49) | SCN9AKCNH2SCN5AAURKAIKBKB | |
| SCHEMBL7158982 | 0.74 | CA12 (0.51) | — | |
| SCHEMBL14311357 | 0.74 | IGF1R (0.63) | SYKIKBKB | |
| SCHEMBL12346555 | 0.72 | SCN9A (0.59) | SCN9AKCNH2SCN5ASYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140073627-A1 | BRADYKININ B1 ANTAGONISTS | EVOTEC AG (DE) | 2014-03-13 | — | — | US | disclosed |
| US-8623859-B2 | Bradykinin B1 antagonists | EVOTEC AG (DE) | 2014-01-07 | — | — | US | disclosed |
| EP-2331518-A1 | NEW BRADYKININ B1 ANTAGONISTS | Evotec AG (DE) | 2011-06-15 | — | — | EP | disclosed |
| WO-2010020556-A1 | NEW BRADYKININ B1 ANTAGONISTS | EVOTEC NEUROSCIENCES GMBH (DE) | 2010-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140073627-A1 | BRADYKININ B1 ANTAGONISTS | BDKRB1, BDKRB2, BRS3 | SCN9A 1141/4885KCNH2 148/4885SCN5A 1356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.